Clinical Trial Update: ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of acalabrutinib (ACP-196) in combination with pembrolizumab in hematologic malignancies has completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Follicular Lymphoma
• Hodgkin Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Richter Transformation
• Small Lymphocytic Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Calquence (acalabrutinib) (acalabrutinib)
• Keytruda (Pembrolizumab) (pembrolizumab)

Snippet

Sponsor: Acerta Pharma BV | Conditions: Follicular Lymphoma (FL), CLL | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-05-06